






































Manual Thrombus Aspiration and the Improved Survival of
Patients With Unstable Angina Pectoris Treated With
Percutaneous Coronary Intervention (30 Months Follow-Up)
Bekir S. Yildiz, MD, Murat Bilgin, MD, Mustafa Zungur, MD, Yusuf I. Alihanoglu, MD,
Ismail D. Kilic, MD, Ipek Buber, MD, Ahmet Ergin, Havane A. Kaftan, and Harun Evrengul
Abstract: The clinical effect of intracoronary thrombus aspiration
during percutaneous coronary intervention in patients with unstable
angina pectoris is unknown. In this study, we aimed to assess how
thrombus aspiration during percutaneous coronary intervention affects
in-hospital and 30-month mortality and complications in patients with
unstable angina pectoris.
We undertook an observational cohort study of 645 consecutive
unstable angina pectoris patients who had performed percutaneous
coronary intervention from February 2011 to March 2013. Before
intervention, 159 patients who had culprit lesion with thrombus were
randomly assigned to group 1 (thrombus aspiration group) and group 2
(stand-alone percutaneous coronary intervention group). All patients
were followed-up 30 months until August 2015.
Thrombus aspiration was performed in 64 patients (46%) whose
cardiac markers (ie, creatinine kinase [CK-MB] mass and troponin T)
were significantly lower after percutaneous coronary intervention than
in those of group 2 (CK-MB mass: 3.80 1.11 vs 4.23 0.89,
P¼ 0.012; troponin T: 0.012 0.014 vs 0.018 0.008, P¼ 0.002).
Left ventricular ejection fraction at 6, 12, and 24 months postinterven-
tion was significantly higher in the group 1. During a mean follow-
up period of 28.87 6.28 months, mortality rates were 6.3% in the
group 1 versus 12.9% in the group 2. Thrombus aspiration was also
associated with significantly less long-term mortality in unstable
angina pectoris patients (adjusted HR: 4.61, 95% CI: 1.16–18.21,
P¼ 0.029).
Thrombus aspiration in the context of unstable angina pectoris is
associated with a limited elevation in cardiac enzymes during inter-
vention that minimises microembolization and significantly improves
both of epicardial flow and myocardial perfusion, as shown by
angiographic TIMI flow grade and frame count. Thrombus aspiration
during percutaneous coronary intervention in unstable angina pectoris
patients has better survival over a 30-month follow-up period.
(Medicine 95(8):e2919)
Abbreviations: ACS = acute coronary syndrome, CABG =
coronary artery bypass grafting, CAD = coronary artery disease,
CHF = congestive heart failure, CK-MB mass = creatinine kinase
MB mass, CPM = cardiac pacemaker, CRT-D/P = cardiac
resynchronization therapy and defibrillator/pacemaker, Cx =
circumflex, DES = drug-eluting stent, GRACE = Global Registry
of Acute Coronary Events, HF = heart failure, ICD = implantable
cardioverter defibrillator, LAD = left anterior descending, LMCA =
left main coronary artery, LV volume = left venticular volume,
LVEF = left ventricular ejection fraction, MBG = myocardial blush
grade, NSTEMI = non-ST-segment elevation myocardial infarction,
PCI = percutaneous coronary intervention, QCA = quantitative
coronary angiography, RCA = right coronary artery, REMEDIA =
randomized evaluation of the effect of mechanical reduction of
distal embolization by thrombus-aspiration in primary and rescue
angioplasty, STEMI = ST-segment elevation myocardial infarction,
TA = thrombus aspiration, TAPAS = Thrombus Aspiration During
Percutaneous Coronary Intervention in Acute Myocardial
Infarction Study, TASTE = Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia, TFC = TIMI frame count,
TIMI = thrombolysis in terms of myocardial infarction, UAP =
unstable angina pectoris.
INTRODUCTION
U nstable angina pectoris (UAP) is the subset of acutecoronary syndromes (ACS) caused by the erosion or
rupture of atherosclerotic plaque and thrombosis.1,2 The preva-
lence of coronary thrombus has been estimated at 10% to 80%
in patients with UAP.3 Primary therapy is often urgently needed
and/or involves elective percutaneous coronary intervention
(PCI).2 During PCI, the percutaneous dilatation of coronary
stenosis inevitably causes plaque disruption, which may in turn
cause the distal embolization of plaque debris or thrombus
material. Myocardial tissue reperfusion often reduces due to
distal vascular debris embolization that prompts the plugging
of the microvasculature, microvascular dysfunction, and
myocardial necrosis.4
Recent studies using thrombectomy or a distal protection
apparatus in primary PCI for ST segment elevation myocardial
infarction (STEMI) have demonstrated that using such appa-
ratuses can significantly reduce the incidence of distal embo-
lization and improve both myocardial perfusion and clinical
outcomes.5–9 Favorable outcomes have also been reported in
patients with non-STEMI (NSTEMI) if angiography suggested
the presence of thrombus formation.10 That study’s analysis
included PCI patients with UAP, in each of whom the appli-
cation of manual aspiration catheter for thrombus aspiration
(TA) during PCI was insufficient.11 Currently, no published
data comparing TA in patients with UAP are available. The
primary aim of this observational study was to assess how TA
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during PCI effects in-hospital and 30-month mortality in UAP
patients. Its secondary aim was to assess this effect in relation to
regional and global contractile left ventricular (LV) function, as
well as examine how TA impacts on post-PCI thrombolysis in
terms of myocardial infarction (TIMI) flow, TIMI frame count
(TFC), and myocardial blush grade (MBG).
MATERIALS AND METHODS
Study Design and Population
The present research entailed a multicenter, retrospective,
observational, cohort study involving the blind evaluation of
end points confirmed by the local ethics committee and in
accordance with the Declaration of Helsinki. We retrospectively
studied 159 patients selected among 645 UAP patients con-
secutively referred to the catheterization laboratory of our
institutions for coronary angiography and angioplasty. The
analysis comprised PCI patients with UAP in each of whom
the export aspiration catheter was applied for TA during PCI at
Pamukkale University and Sifa University between February
15, 2011 and March 1, 2013. All patients were followed-up 30
months until August 1, 2015 except death.
UAP was defined as the occurrence of typical chest pain at
rest with or without electrocardiographic signs of ischemia yet
without ST elevation or increase in cardiac troponin T greater
than 0.01 ng/ml and creatinine kinase-MB (CK-MB) mass
greater than 5 ng/ml (ie, local laboratory threshold of myo-
cardial infarction). Inclusion criteria for UAP patients were
thrombus burden vessel diameter greater than 2.5 mm, and
technical viability for angioplasty independent of both initial
TIMI flow and angiographic evidence of intraluminal thrombus
in the culprit artery. Thrombus was defined as the presence of a
roundish filling defect of the lumen during dye injection (in
multiple projections either) with or without the persistence of
luminal contrast following injection. Patients who had been
taking anticoagulants and presented with cardiogenic shock
and/or thrombus formation as a complication of a PCI (eg,
vessel closure after stenting) were excluded from the sample.
Other exclusion criteria were the known existence of a disease
resulting in a life expectancy less than 6 months, and the lost of
patient during follow-up. Patients with echocardiographic ima-
ge of a poor quality were not accepted for the study. No other
clinical exclusion criteria were adopted. The echocardiographic
acoustic window was assessed in the emergency department or
catheter laboratory by a staff cardiologist before the procedures.
After enrollment and before PCI, 159 patients who had culprit
lesion with thrombus were randomly assigned to group 1 (TA
group) and group 2 (stand-alone PCI group) according to a
computer-generated random series of numbers (Figure 1).
FIGURE 1. Flow diagram of the study profile.
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Procedure
In all patients catheterization was performed following the
femoral approach by experienced cardiologists. To begin, a
steerable guide wire was passed through the target lesion; direct
stenting was left to the operator’s discretion and usually per-
formed according to patent vessel with no or mild calcification.
In patients in the group 2, this step was followed by balloon
dilation to assure antegrade flow where as in those in the group
1, the step was followed by advancing the 6F export aspiration
catheter (Medtronic, Minneapolis, MN), a 6F-compatible TA
catheter with an aspiration lumen of 0.041 in. and cross profile
of 0.068 in., which was handled over a guide wire of 0.014 in. in
a monorail fashion. Suction was performed manually with
lockable 20-ml syringes. After crossing the lesion with a guide
wire, the export aspiration catheter was advanced into the target
segment during continuous aspiration. The number of passages
necessary to achieve an optimal result was left to the judgment
of the operator, but at least 2 20 ml was aspirated in multiple
passages. Additional balloon angioplasty was performed when
necessary for stent delivery. After restoring the antegrade flow,
in patients deemed suitable intracoronary nitrates were given to
achieve maximal epicardial vasodilation, largely to determine
the length, and size of the stent and facilitate stent placement.5
After placement, PCI postprocedural peak creatinine kinase MB
mass (CK-MB) mass and troponin T level were measured.
Measurement of CK-MB mass and troponin T were also
repeated in 6, 24, and 48 h after PCI. Totally cardiac enzymes
were measured 4 times after PCI.
Medication
Pharmacological treatment before and after PCI was per-
formed according to European Society of Cardiology guideline.12
Angiographic and Echocardiographic Analysis
Coronary angiograms were performed digitally (INNOVA
2100, GE Healthcare, Waukesha, WI). Calibration of the quan-
titative coronary angiography (QCA) system was carried out by
method in which the coronary catheter employed for angio-
graphy and was used as the calibration object by automated
edge detection technique resulting in corresponding calibration
factors (mm/pixel). The coronary artery contour was detected
by operator independent edge detection algorithms. The dimen-
sion of the coronary artery was then measured as a function of
catheter diameter; the absolute diameter in mm was calculated
by the computerized software analysis. At least 2 orthogonal
projections of the coronary segment scheduled for coronary
intervention were filmed before and after the intervention. All
angiograms were evaluated and reviewed offline by 2 experi-
enced, interventional cardiologists blind both the results and
success of the technique, as stated in the procedural report, for
the presence of intraluminal filling defects and TIMI flow grade
before PCI, after TA, and at the end of the procedure. The
feasibility, success rate, and occurrence of potential compli-
cations (eg, coronary dissection and perforation) due to TAwere
reported. The applicability of the aspiration procedure was
defined as the ability to advance the aspiration catheter into
the target lesion without predilatation, while the accomplish-
ment of TA was defined as the visually determined reduction of
intraluminal filling defects in the angiogram and/or the presence
of visible thrombus in the aspirate. Improvement in coronary
flow due to TA was defined as the improvement in TIMI flow
grade by at least one grade. Distal embolization during PCI was
defined as the presence of a new distal occlusion of either the
treated vessel or one of its side branches or the migration of a
filling defect. No reflow was defined as TIMI flow grade 0 to 1 not
due to occlusive thrombus formation, dissection, or coronary
artery spasm. Baseline, postaspiration, and final post-PCI angio-
graphic coronary flows were also assessed by means of the
corrected TFC at 12.5 frames/s.13 Baseline and final post-PCI
MBGs were determined.14 Clinical status in terms of stroke,
reinfarction, bleeding, pacemaker implantation, rehospitalization
for heart failure (HF), target vessel revascularization, and death
was determined from hospital records as well as by face to face
interviews at 1, 6, 12, 24, and 30 months after the procedure.
LV ejection fraction (LVEF) and LV volumes were
measured with the modified Simpson rule algorithm by echo-
cardiography.15 The mean value of 3 measurements of the
technically best cardiac cycles was taken from each examin-
ation. LVEF and LV volume changes at 6, 12, and 24 months
were compared within 24 h of admission. Intraobserver and
interobserver variability values in the evaluation of end-dias-
tolic and -systolic volumes were<5%, which suggests the good
reproducibility of the measurements.16
Hospital Complications and Study End Points
In-hospital complications such as recurrent MI, stent throm-
bosis, atrial fibrillation, ventricular fibrillation, major bleeding
(hemoglobin drop of 3–5 g% or need for blood transfusion, a drop
in hemoglobin 5 g%, cardiac tamponade, need for surgical
treatment or hemodynamic instability, and intracranial or intra-
ocular bleeding), stroke, and acute renal failure were noted, in
addition to 30-month mortality, complications, and major adverse
cardiovascular events over a 30-month follow-up in patients
undergoing PCI. The 30-month follow-up was 95% complete.
The primary end point was all-cause mortality at 30-month
follow-up. We here report the following prespecified secondary
end points: stroke, rehospitalization for MI and congestive heart
failure (CHF), cardiac pacemaker (CPM), implantable cardio-
verter defibrillator (ICD) or cardiac resynchronization therapy
and defibrillator/pacemaker (CRT-D/P) implantation, stent
thrombosis, and target-lesion revascularization. The incidence
of bleeding complications was assessed both during PCI and at
30 months following PCI.
Statistical Analysis
For quantitative variables, M and SD were calculated.
Discrete variables are here presented as the number of events
and their percentages. Comparisons were made with Chi-square
or Fisher exact tests for discrete variables and by unpaired t
tests, Wilcoxon sign-rank tests, or 1-way analyses of variance
(ANOVA) for continuous variables. Repeated measured
ANOVA was used for repeatedly measured variables. Survival
curves were estimated using the Kaplan–Meier estimator and
compared using log-rank tests while correlates of 30-month
survival were determined using a multivariate backward step-
wise Cox analysis. Cumulative hazard functions were computed
to assess proportionality, and differences were considered sig-
nificant at P< 0.05. Statistical analyses were performed by
using the Statistical Package for the Social Sciences for Win-
dows version 17 (SPSS, Chicago, IL).
RESULTS
Patient and Procedural Data
A total of 139 UAP patients (mean age 65.02
13.00 years, 69.1% male) were studied, 64 of whom 46%
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underwent thrombectomy. TA was attempted before PCI in
UAP patients (aged 64.28 12.7 years) who had angiography-
detected of thrombus formation. Four hundred eighty-six
patients were excluded from analysis (Figure 1). There were
no statistically significant between-group differences in age,
sex, duration of chest pain, risk factors (ie, body mass index,
diabetes mellitus, hypertension, hyperlipidemia, smoking, renal
insufficiency, family history and history of coronary artery
disease [CAD], coronary artery bypass grafting [CABG],
cerebrovascular accident, CHF, and peripheral artery disease),
ECG parameters (ie, heart rate and rhythm at admission), blood
parameters, drugs or medication taken before admission, LVEF
within 24 h, Global Registry of Acute Coronary Events
(GRACE) score, and Killip classification at admission. Baseline
demographics and clinical characteristics are shown in Table 1.
The culprit coronary artery was the right coronary artery
(RCA) in 34.4% of the group 1 and in 22.7% of the group 2, the
left anterior descending artery (LAD) in 48.4% and 56% of the 2
groups, the left circumflex artery (Cx) in 15.6% and 18.7%, and
the left main coronary artery (LMCA) in 1.6% and 2.7%
(P< 0.486). Three and more vessel disease was present in
17.2% of patients in the group 1 versus 28% of patients in
the group 2. Stent implantation was performed in 92.2% of
patients in the group 1 and in 98.7% in the group 2. The use of a
drug-eluting stent (DES) was similar in both groups
(P¼ 0.268). Direct stenting was performed in 46 patients
(34%). Cardiac markers (ie, CK-MB mass and troponin T)
were significantly lower after PCI in the group 1 than the group
2 (CK-MB mass: 3.80 1.11 vs 4.23 0.89, P¼ 0.012; tropo-
nin T: 0.012 0.014 vs 0.018 0.008, P¼ 0.002). There were
no statistically significant between-group differences in occlu-
sion pre-PCI, balloon angioplasty, balloon length and diameter,
balloon inflation time, indeflator pressure, stent diameter and
length, stent balloon inflation time, indeflator pressure for stent
balloon, stent postdilatation, or procedure complication (eg,
coronary dissection, coronary perforation, hematoma, and arter-
iovenous fistula). Duration of hospitalization was statistically
briefer in the group 1 than in the group 2 (4.25 4.02 day vs
6.49 5.83 day, P¼ 0.011). The use of anticoagulants and
antiaggregants was generally similar between both groups, as
was treatment by statins, b-blockers, ACEi, or ARB during the
first 24 h. TA was associated with an increased rate of TIMI-
flow 3 (37.5% in group 1 and 34.7% in the group 2 preprocedure
vs 93.8% and 78.7%, respectively, at the end of procedure). The
number of patients with postoperative TIMI grade 3 blood flow
was significantly higher in the group 1 (P¼ 0.036). The number
of patients with a no-reflow rate was lower in the group 1 than in
the group 2, though not significantly (P¼ 0.687) while the
incidence of MBG 3 was 90.6% and 70.3%, respectively
(P¼ 0.031). TFCs were significantly decreased in infarct
related arteries in both groups after PCI. The decrease in TFCs
was far greater in the group 1 than in the group 2 and statistically
significant (Table 2). Furthermore, a significant decrease in
TFCs also emerged following aspiration in all coronary arteries
in group 1 (TFC-LAD preaspiration: 25.93 4.46 vs postas-
piration: 17.25 2.17, P¼ 0.001; TFC-CX preaspiration:
20.07 2.46 vs postaspiration: 14.35 2.06, P¼ 0.001; TFC-
RCA preaspiration: 18.20 5.33 vs postaspiration: 14.65
2.59, P¼ 0.001) (Table 3).
At 6, 12, and 24 months post-PCI, the mean LVEF was
significantly higher in the group 1 versus the group 2 (Figure 2).
In-hospital mortality, stroke, stent thrombosis, major
bleeding, recurrent MI, onset of atrial fibrillation (AF) or
ventricular tachycardia/ventricular fibrillation (VT/VF), and
acute renal failure were not significantly different between
the 2 groups (Table 4).
Death, stroke, bleeding complications, recurrent MI, stent
thrombosis, occurrence of AF, occurrence of VT/VF, new renal
dialysis, new CABG, rehospitalization for HF, CPM implan-
tation, ICD or CRT-D/P implantation were assessed within 30
months following PCI. Death was significantly lower in the
group 1 (unadjusted OR: 0.29, 95% CI: 0.09–0.93, P¼ 0.030).
In a multiple logistic regression model adjusted for age, sex,
systolic blood pressure, glomerular filtration rate, multivessel
CAD, GRACE score at admission, initial TIMI flow, LVEF at 6
months, or concomitant use of GP IIb–IIIa inhibitors, TA was
associated with a significant reduction in 30-month mortality
(adjusted OR: 7.36, 95% CI: 1.20–45.10, P¼ 0.031). Stroke,
recurrent MI, occurrence of AF, occurrence of VT/VF, ICD
implantation, rehospitalization for HF, new CABG were also
significantly lower in the group 1 than in the group 2 (Table 5).
During a mean follow-up period of 28.87 6.28 months
(30.18 4.16 months in the group 1 vs 27.76þ 7.49 months in
the group 2), 18 patients (12.9%) died. Of these, 4 patients were
from the group 1 (6.3%) and 14 from the group 2 (18.7%)
(unadjusted HR: 3.24, 95% CI: 1.06–9.58, P¼ 0.038). Using
Cox multivariate analysis, TA was associated with significantly
less long-term mortality even after the same variables were
corrected in all UAP patients (adjusted HR: 4.61, 95% CI:
1.16–18.21, P¼ 0.029). The Kaplan–Meier cumulative survive
curve appears in Figure 3.
DISCUSSION
In this trial, the process of manual TA during PCI in
patients with UAP and thrombus-containing lesions was found
to be associated with better long-term survival and lower rates
of stroke, recurrent MI, arrhythmias (AF, VT/VF), rehospita-
lization for CHF, and new CABG and ICD implantation within
30 months than in patients treated with PCI only. To the best of
our knowledge, this study is the first of PCI-treated UAP
patients to have demonstrated an association between TA
and reduced mortality.
Previous studies assessing the use of TA in STEMI patients
and its outcomes have demonstrated different results.5,8,17–20
The Thrombus Aspiration during Percutaneous Coronary Inter-
vention in Acute Myocardial Infarction Study (TAPAS) is the
only randomized trial to have demonstrated a significant
beneficial effect on mortality: an approximately 50% reduction
in 1-year mortality.8 Conversely, the Thrombus Aspiration in
ST-Elevation Myocardial Infarction in Scandinavia (TASTE)
study showed that routine thrombectomy use did not reduce 30-
day mortality.21 Similar conflicting results were demonstrated
in NSTEMI patients. Vlaar et al10 found that manual TA was
associated with a significant reduction of TIMI thrombus score
and an increased rate of TIMI flow grade 3 in NSTEMI patients.
Thiele et al22 showed that TA in conjunction with PCI in
NSTEMI with a thrombus-containing lesion did not precipitate
any reduction in microvascular obstruction. Hermens et al11
published their initial experiences with manual TA in 14
patients with stable or UAP and recommended that myocardial
perfusion might benefit from TA in patients with stable or
unstable angina. Based on these data, current American and
European guidelines suggest performing manual TA in only
STEMI patients with a class IIa level of evidence B recom-
mendation.23,24
In this study, manual TA was associated with a significant
reduction of TFC and an increase in the rate of TIMI flow 3 and
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TABLE 1. Baseline Characteristics of Study Population
Thrombus Aspiration Stand-Alone PCI
(n) MeanSD (%) (n) Mean SD (%) P
Age (y) 64.28 12.70 65.65 13.30 0.537
Duration of chest pain (h) 6.85 3.62 7.07 4.32 0.755
Sex 0.941
Female 20 31.3 23 30.7
Male 44 68.8 52 69.3
Risk factors
BMI (kg/m2) 26.00 2.30 26.08 2.51 0.846
DM 24 37.5 25 33.3 0.608
HT 39 60.9 40 53.3 0.367
HLP 13 20.3 19 25.3 0.483
Smoking 19 29.7 25 33.3 0.645
Family history 10 15.6 11 14.7 0.875
History
Previous CAD 12 18.8 17 22.7 0.571
Previous PAD 5 7.8 6 8.0 0.967
Previous CABG 7 10.9 8 10.7 0.959
Previous CVA 3 4.7 5 6.7 0.726

Previous CHF 5 7.8 4 5.3 0.732

Chronic renal failure 9 14.1 15 20.0 0.356
Clinical
SBP (mm Hg) 143.73 11.83 142.45 16.49 0.605
DBP (mm Hg) 85.39 14.06 83.98 17.53 0.608
ECG
HR beats/min 78.14 19.24 75.61 16.54 0.406
Rhythm at admission 0.754
SR 57 89.1 68 90.7
AF 7 10.9 7 9.3
RBBB 7 10.7 6 8.0 0.553
LBBB 12 18.8 11 14.7 0.518
AV block 11 17.2 20 26.7 0.181
Bloods
Hg (g/dl) 13.01 2.37 13.34 1.78 0.354
Plt (k/ml) 232.10 41.52 220.44 51.50 0.148
WBC (k/ml) 7.74 1.55 7.50 1.30 0.328
Urea (mg/dl) 37.09 14.26 42.32 22.25 0.108
Creatinine (mg/dl) 1.01 0.27 1.01 0.29 0.978
GFR (ccs/min) 83.71 33.54 76.25 31.75 0.181
Hs-CRP (mg/L) 2.79 1.20 2.59 0.93 0.272
Uric acid (mg/dl) 7.03 2.18 7.21 1.86 0.615
Glucose (mg/dl) 132.35 36.98 134.40 69.32 0.833
CK-MB mass (ng/ml)y 2.39 0.97 2.26 1.06 0.456
Troponin T (ng/ml)z 0.0034 0.0038 0.0034 0.0040 0.910
LDL cholesterol (mg/dl) 112.34 31.99 109.02 28.07 0.516
HDL cholesterol (mg/dl) 42.62 9.43 40.68 11.28 0.277
Triglyceride (mg/dl) 208.14 86.71 197.28 109.62 0.523
Total cholesterol (mg/dl) 192.70 26.44 195.90 32.64 0.531
Drugs before admission
Aspirin 22 34.4 34 45.3 0.189
Clopidogrel 13 20.3 14 18.7 0.807
ACEi or ARB 34 53.1 42 56.0 0.734
b-blocker 36 56.3 36 48.0 0.332
Statin 17 26.6 26 34.7 0.303
LVEF%
Within 24 h 47.26 9.87 46.21 9.94 0.534
GRACE score (death) 93.62 24.79 100.40 18.33 0.067
GRACE score (deathþMI) 114.40 28.69 122.86 22.74 0.055
Admission Killip class 1.34 0.47 1.32 .52 0.782
ACEi¼ angiotensin converting enzyme inhibitor, AF¼ atrial fibrillation, ARB¼ angiotensin receptor blocker, AV block¼ atrioventricular block,
BMI¼ body mass index, CABG¼ coronary artery bypass grafting, CAD¼ coronary artery disease, CHF¼ congestive heart failure, CK-MB
mass¼ creatinine kinase MB mass, CVA¼ cerebrovascular accident, DBP¼ diastolic blood pressure, DM¼ diabetes mellitus, GFR¼ glomerular
glomerular filtration rate, HDL¼ high density lipoprotein, Hg¼ hemoglobin, HLP¼ hyperlipidemia, HR¼ heart rate, HT¼ hypertension,
LBBB¼ left bundle branch block, LDL¼ low density lipoprotein, LVEF¼ left ventricular ejection fraction, NSTEMI¼ non-ST-segment elevation
myocardial infarction, PAD¼ peripheral artery disease, PCI¼ percutaneous coronary intervention, Plt¼ platelet, RBBB¼ right bundle branch block,
SBP¼ systolic blood pressure, SD¼ standard deviation, SR¼ sinus rhythm, STEMI¼ST-segment elevation myocardial infarction, UAP¼ unstable
angina pectoris, VT¼ ventricular tachycardia, WBC¼white blood cell.
Fischer exact test was used.
yCK-MB mass normal range: 0–5 ng/ml.
zTroponin T normal range: 0–0.014 ng/ml.
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TABLE 2. Procedural Characteristics, Angiographic, and Echocardiographic Results of Study Population
Thrombus Aspiration Stand-Alone PCI
(n) MeanSD (%) (n) MeanSD (%) P
Culprit coronary vessel 0.486
LMCA 1 1.6 2 2.7
CX 10 15.6 14 18.7
LAD 31 48.4 42 56
RCA 22 34.4 17 22.7
CAD extension 0.036
1 vessel 37 57.8 27 36.0
2 vessels 16 25.0 27 36.0
3 and more vessels 11 17.2 21 28.0
Balloon angioplasty 51 79.7 53 70.7 0.222
Stent implanted 61 95.3 74 98.7 0.334

Stent type 0.684
BMS 22 34.4 30 40.0
DES 39 60.9 43 57.3
Direct stenting 19 29.7 27 36.0 0.476
Occlusion pre-PCI (%) 92.17 4.46 90.71 6.32 0.212
Balloon diameter (mm) 1.81 1.13 1.67 1.26 0.500
Balloon length (mm) 13.72 8.19 12.52 9.91 0.444
Balloon inflation time (s) 27.58 18.12 27.60 22.27 0.995
Indeflator pressure (atm) 10.34 5.62 9.45 7.08 0.419
Stent diameter (mm) 2.80 0.82 2.84 0.61 0.773
Stent length (mm) 20.89 8.58 21.69 10.89 0.634
Stent balloon inflation time (s) 20.47 9.98 19.07 7.38 0.344
Indeflator pressure for stent balloon (atm) 14.70 3.80 14.64 3.03 0.920
Stent postdilatation 7 10.9 7 9.3 0.754
No-reflow 2 3.1 4 5.3 0.687

Procedure complication 10 15.6 10 13.3 0.701
Procedure complication type 0.572
Coronary dissection 4 40.0 2 20.0
Coronary perforation 0 0 1 10.0
Hematoma 5 50.0 5 50.0
Arteriovenous fistula 1 10.0 2 20.0
Post-PCI CK-MB mass (ng/ml) 3.80 1.11 4.23 0.89 0.012
Post-PCI troponin T (ng/ml) 0.012 0.014 0.018 0.008 0.002
Hospitalization time (d) 4.25 4.02 6.49 5.83 0.011
Drugs
Glycerol trinitrate (before/during angiography) 16 25.0 23 30.7 0.459
Glycoprotein IIb–IIIa inhibitors
(before/during angiography)
12 18.8 8 10.7 0.176
Ca-channel blocker (before/during angiography) 8 12.5 8 10.7 0.736
Aspirin in first 24 h 62 96.9 73 97.3 0.872
Clopidogrel first 49 76.6 55 73.3 0.662
Prasugrel first 5 7.8 6 8.0 0.967
LMWH (before/during angiography) 49 76.6 47 62.7 0.077
UFH (before/during angiography) 31 48.4 46 61.3 0.127
Statin in first 24 h 39 60.9 52 69.3 0.299
ACEi or ARB in first 24 h 30 46.9 33 44.0 0.734
b blockers in first 24 h 29 45.3 37 49.3 0.636
TIMI flow before PCI 0.718
1 9 14.1 8 10.7
2 31 48.4 41 54.7
3 24 37.5 26 34.7
TIMI flow after PCI 0.036
1 1 1.6 2 2.7
2 3 4.7 14 18.7
3 60 93.8 59 78.7
Myocardial blush grade pre-PCI 0.553
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MBG 3 in the manual TA group. Vlaar et al10 found an increase
in TIMI 3 flow after TA in NSTEMI patients while Burzotta
et al17 found significant improvement of MBG in patients with
successful TA in STEMI patients. In our study, postprocedural
levels of CK-MB mass and troponin T were higher in the stand-
alone PCI group than in the TA group. These results show
that TA reduces thrombus burden and prevents distal emboliza-
tion in causing microvascular injury. Thereby, increased micro-
vascular flow improves myocardial reperfusion and clinical
outcomes.25,26
In the present study, we also evaluated LV functions of
UAP patients, and baseline LVEFs were similar between the 2
Thrombus Aspiration Stand-Alone PCI
(n) MeanSD (%) (n) MeanSD (%) P
1 10 15.6 8 10.7
2 34 53.1 46 61.3
3 20 31.3 21 28
Myocardial blush grade post-PCI 0.031
1 1 1.6 2 2.7
2 5 7.8 18 24.0
3 58 90.6 55 73.3
TIMI frame count
LAD
Pre-PCI 31 25.93 4.46 42 24.01 2.76 0.050
Post-PCI 31 15.43 3.07 42 18.18 1.39 0.001
Cx
Pre-PCI 10 21.00 3.65 14 20.07 2.46 0.438
Post-PCI 10 13.78 2.69 14 16.78 2.11 0.003
RCA
Pre-PCI 22 18.20 5.33 17 18.62 3.30 0.779
Post-PCI 22 14.13 2.48 17 16.12 3.00 0.027
EF%
After 6 months post-PCI 63 53.12 8.57 73 49.54 10.12 0.029
After 12 months post-PCI 63 52.38 10.62 70 48.18 12.19 0.037
After 24 months post-PCI 62 52.54 11.39 61 48.03 11.86 0.033
ACEi¼ angiotensin converting enzyme inhibitor, ARB¼ angiotensin receptor blocker, BMS¼ bare metal stent, CAD¼ coronary artery disease,
Cx¼ circumflex, CK-MB mass¼ creatinine kinase MB mass, DES¼ drug eluting stent, LAD¼ left anterior ascending, LMCA¼ left main coronary
artery, LMWH¼ low molecular weight heparin, NSTEMI¼ non-ST-segment elevation myocardial infarction, PCI¼ percutaneous coronary
intervention, RCA¼ right coronary artery, SD¼ standard deviation, STEMI¼ST-segment elevation myocardial infarction, TIMI¼ thrombolysis
in myocardial infarction, UAP¼ unstable angina pectoris, UFH¼ unfractionated heparin.
Bold value signifies statistically significant.
Fischer exact test was used.
TABLE 3. Comparison of TIMI Frame Counts of All Patients
TIMI Frame Count
Thrombus







LAD (n¼ 31) 25.93 4.46 17.25 2.17 15.43 3.07 0.001 0.001 0.028
CX (n¼ 10) 20.07 2.46 14.35 2.06 13.78 2.69 0.001 0.001 0.120
RCA (n¼ 22) 18.20 5.33 14.65 2.59 14.13 2.48 0.001 0.001 0.037
TIMI Frame Count
Thrombus Aspiration () Pre-PCI Post-PCI P, Pre-PCI–Post-PCI
LAD (n¼ 42) 24.01 2.74 18.18 1.39 0.001
CX (n¼ 14) 21.00 3.65 16.78 2.11 0.001
RCA (n¼ 17) 18.62 3.30 16.12 3.00 0.001
Cx¼ circumflex, LAD¼ left anterior descending, PCI¼ percutaneous coronary intervention, Post-asp¼ postthrombus aspiration, Pre-asp¼
prethrombus aspiration, RCA¼ right coronary artery, TIMI¼ thrombolysis in terms of myocardial infarction.
Bold value signifies P< 0.05.
TABLE 2. (Continued)
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groups. By the time that LVEFs were changed in 6, 12, and 24
months after PCI in both groups. LVEF was significantly higher
in the TA group than in the stand-alone group during 24 months.
The LVEF increases in both groups at the 1st echo during
follow-up, then goes down and plateaus in the thrombectomy
group while declining further in the nonthrobectomy group. We
may accept that LVEF is acutely depressed or biomarker release
(hibernation) and that it improves after revascularization.
Decrease in LVEF in the stand-alone PCI group after 6 months
may be explained by higher incidence of complications like
recurrent MI in this group. Similarly, Liistro et al27 showed that
manual TA in the context of primary PCI improves myocardial
tissue-level perfusion as well as LV functional recovery and
remodeling at 6 months. Conversely, in the myocardial contrast
echocardiographical substudy of the REMEDIA trial.28 TA was
associated with no significant reduction in LV remodeling at 6
months. Despite conflicting results, our findings suggest that
TA may help to reduce the infarct size and preserve the
myocardial function by protecting microvascular obstruction.
According to our study, TA appears to be a valuable
approach to improving outcomes in UAP patients with visible
thrombus. In this study, improved procedural outcomes with
manual TA were observed, though these improvements were
not associated with better hospital mortality or in-hospital
complication rates. Although there was no significant difference
in relationship to hospital complications, duration of hospital-
ization was significantly briefer in the TA group. Lower long-
term complication rates may be attributed to the use of TA
during PCI, since TA may help to reduce infarct size, prevent
cardiac remodeling, and/or preserve myocardial function by
FIGURE 2. Two-year LVEF according to the use of thrombus
aspiration in UAP patients. P values come from repeated measured
analysis of variance.
TABLE 4. In-Hospital Complications
Thrombus Aspiration Group Stand-Alone PCI Group P, Odds Ratio (95% CI)
Death 1.000

(n) 1 2 0.579
(%) 1.6 2.7 (0.051–6.542)
Stroke 0.624

(n) 1 3 0.381
(%) 1.6 4 (0.039–3.755)
Stent thrombosis 0.452

(n) 2 5 0.452
(%) 3.1 6.7 (0.085–2.411)
Major bleeding 0.993
(n) 6 7 1.005
(%) 9.4 9.3 (0.320–3.159)
Recurrent MI 0.624

(n) 1 3 0.381
(%) 1.6 4 (0.039–3.755)
Onset AF 0.343
(n) 6 11 0.602
(%) 9.4 14.7 (0.209–1.731)
Onset VT/VF 0.086
(n) 2 8 0.270
(%) 3.1 10.7 (0.055–1.322)
Acute renal failure 0.291
(n) 3 7 0.478
(%) 4.7 9.3 (0.118–1.930)
AF¼ atrial fibrillation, CI¼ confidence interval, NSTEMI¼ non-ST-segment elevation myocardial infarction, PCI¼ percutaneous coronary
intervention, STEMI¼ST-segment elevation myocardial infarction, UAP¼ unstable angina pectoris, VT/VF¼ ventricular tachcardia, ventricular
fibrillation.
Fischer exact test was used.
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protecting microvascular obstruction. Lower stroke rates up
until the 30-month follow-up in our study can be explained by a
significant reduction in the onset of AF or VT/VF.
Study Limitations
In this study, for UAP patients the decision to perform TA
was made after careful consideration by experienced interven-
tional cardiologists. Nevertheless, absent the use of intravas-
cular ultrasound or optical coherence tomography, even
experienced operators have a limited ability to distinguish
intracoronary thrombus formation from calcified lesions. Our
data lack information on culprit lesion characteristics (eg,
target-vessel tortuosity). In addition, we have not standardized
our determination of whether the aspiration catheter crossed the
culprit lesion and lacked information concerning the amount of
thrombus material removed. Also, the study population
remained small.
CONCLUSIONS
This study demonstrates that manual TA in the context of
UAP is associated with a limited elevation in cardiac enzymes
during PCI that minimizes microembolization with a significant
improvement both of the coronary artery flow and myocardial
perfusion, as assessed by the use angiographic TIMI flow grade,
TFC, and MBG. The improvement in tissue perfusion is also
TABLE 5. Comparison of Complications Over 30 Months Following in Patients Undergoing Percutaneous Coronary Intervention
(PCI)
Thrombectomy Group Stand-Alone PCI Group P, Odds Ratio (95% CI)
Death 0.030
(n) 4 14 0.290
(%) 6.3 18.7 (0.090–0.933)
Stroke 0.033
(n) 2 10 0.210
(%) 3.1 13.3 (0.044–0.995)
Stent thrombosis 0.246
(n) 4 9 0.489
(%) 6.3 12 (0.143–1.670)
Major bleeding 0.901
(n) 9 10 1.064
(%) 14.1 13.3 (0.403–2.804)
Recurrent MI 0.030
(n) 4 14 0.290
(%) 6.3 18.7 (0.090–0.933)
AF 0.032
(n) 3 12 0.258
(%) 4.7 16 (0.069–0.960)
VT/VF 0.019
(n) 4 15 0.267
(%) 6.3 20 (0.084–0.850)
ICD implantation 0.027
(n) 5 16 0.313
(%) 7.8 21.3 (0.108–0.908)
CRT-D/P implantation 0.506

(n) 3 6 0.566
(%) 4.7 8 (0.136–2.359)
CPM implantation 1.000

(n) 2 2 1.177
(%) 3.1 2.7 (0.161–8.605)
Rehospitalization for HF 0.015
(n) 6 19 0.305
(%) 9.4 25.3 (0.113–0.819)
New renal dialysis 0.051
(n) 3 11 0.286
(%) 4.7 14.7 (0.076–1.075)
New CABG 0.030
(n) 4 14 0.290
(%) 6.3 18.7 (0.090–0.933)
AF¼ atrial fibrillation, CABG¼ coronary artery bypass grafting, CI¼ confidence interval, CPM¼ cardiac pacemaker, CRT-D/P¼ cardiac
resynchronization therapy and defibrillator/pacemaker, HF¼ heart failure, ICD¼ implantable cardioverter defibrillator, NSTEMI¼ non-ST-segment
elevation myocardial infarction, STEMI¼ST-segment elevation myocardial infarction, UAP¼ unstable angina pectoris, VT/VF¼ ventricular
tachycardia/ventricular fibrillation.
Fischer exact test was used.
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associated with a significant improvement in regional and
global LV function at 24 months. Our findings further support
the use of thrombectomy during PCI in UAP patients given its
association with better survival over a 30-month follow-up
period. Using thrombectomy given the suspicion of thrombus
formation in UAP patients affords better results. Nevertheless,
further studies with larger sample sizes are needed to evaluate
the clinical value of and long-term prognosis following
this procedure.
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